Article
Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
General thoracic and cardiovascular surgery - 1 Mar 2009
Yoshimasu Tatsuya, Ohta Fuminori, Oura Shoji, Tamaki Takeshi, Shimizu Yukio, Naito Koma, Kiyoi Megumi, Hirai Yoshimitsu, Kawago Mitsumasa, Okamura Yoshitaka
Abstract excerpt
OBJECTIVE: There are many predictive factors for gefitinib sensitivity, including epidermal growth factor receptor (EGFR) gene mutation, EGFR copy number, and k-ras mutation. To investigate all of them is too expensive. We evaluated the chemosensitivity for gefitinib in non-small-cell lung cancer (NSCLC) using a histoculture drug response assay (HDRA). METHODS: Surgically resected fresh tumor specimens from 22...
Topics
- Adenocarcinoma
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Cell Proliferation
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- ErbB Receptors
- Female